The offering includes a 45-day option for underwriters to purchase an additional 1.125 million shares to cover potential over-allotments. Unlike many similar vehicles, the current structure does not include warrants for investors. The company expects to raise between $75 million and $86.25 million, with the entirety of those proceeds earmarked for a U.S. trust account intended to support a future merger.

Management has allocated approximately $2.5 million outside of the trust to cover operational overhead, including regulatory fees, legal expenses, and deal-sourcing travel. TCGX has a 24-month window to identify and close a transaction within the healthcare or healthcare-related industries. Public shareholders retain the right to redeem their holdings at the time of any proposed merger.